Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Avacta Group, a clinical stage oncology drug company, has announced the appointment of Dr Mark Goldberg as Non-executive Director to the board with immediate effect.
Dr Goldberg is a medical oncologist and haematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer. He is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors.
Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines. He also served on the board of directors of Audentes Therapeutics until its acquisition by Astellas Pharma in 2020. He previously served on the executive management team of Synageva Biopharma from 2011-2014.
Goldberg commented: “I find the Affimer and pre|CISION platforms to be very innovative. I look forward to joining the Board and working with my new Board colleagues and the Avacta management team to develop novel therapies that will improve the lives of patients suffering from cancer.”
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “I am very pleased to welcome Mark to the Board. Mark is a vastly experienced biotech executive and oncologist and Avacta will benefit greatly from his future contributions to the strategy and vision for the therapeutic business.”
Dr Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Mark will be joining the Board of Avacta. Mark’s wealth of experience and expertise will be invaluable as we progress our pipeline of proprietary Affimer and pre|CISION platforms into clinical stage assets.”